AG
CRSP icon

AmeriFlex Group’s CRISPR Therapeutics CRSP Stock Holding History

AmeriFlex Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3K Hold
225
– – 0.01% 804
2026
Q1 		$10.7K Hold
225
– – 0.01% 717
2025
Q4 		$11.8K Buy
225
+115
+105% +$6.89K 0.01% 696
2025
Q3 		$7.13K Sell
110
-145
-57% -$8.32K ﹤0.01% 851
2025
Q2 		$11.9K Sell
255
-600
-70% -$23.2K 0.01% 672
2025
Q1 		$29.1K Hold
855
– – 0.01% 607
2024
Q4 		$35.6K Buy
+855
New +$40.4K 0.02% 512

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AmeriFlex Group's CRSP Position: Q2 2026 in Review

AmeriFlex Group held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 225 shares worth $12.3K. The position accounts for 0.01% of the portfolio, ranked #804.

AmeriFlex Group first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $35.6K in Q4 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • AmeriFlex Group held 225 shares of CRISPR Therapeutics worth $12.3K as of Q2 2026.
  • AmeriFlex Group left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of AmeriFlex Group's portfolio in Q2 2026, its #804 holding.
  • AmeriFlex Group first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • AmeriFlex Group's CRISPR Therapeutics position peaked at $35.6K in Q4 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on AmeriFlex Group's 13F filing for Q2 2026, filed 14 Aug 2026.